anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and method for generating and sending reward messages to users accomplishing goals related to a personalized health behavior plan. Rewards may be issued for reasons such as achieving an ultimate goal, reaching an intermediate goal, or completing a suggested activity such as eating a suggested meal or performing a suggested physical activity. A reward may be a coupon for use at an establishment such as a restaurant, a clothing store, or a fitness center. Rewards may also be checks sent through postal mail or coupons for printing on a personal printer. Reward messages are generated by an expert system based on a user's personalized diet, exercise, or other health plan, goals associated with the plan, and specified preferences. Reward messages are sent to user's portable devices. Current location information may be used to send a user a reward for use at a nearby establishment.
Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.
Done unilaterally, patient is put in the supine position with ipsilateral arm abducted and externally rotated with elbow flexed 90 degrees. High frequency probe is put in the ipsilateral clavipectoral triangle between the clavicle medially and above and the shoulder joint laterally. The pectoralis major and minor and the plane between them are identified guided by pulsating thoracoacromial artery or its pectoral branch. Needle is advanced in plane targeting the space where the artery is located, 2ml of normal saline is injected to confirm the location. Then, 10 ml of bupivacaine 0.25% is injected. Probe is moved laterally and caudally towards the anterior axillary fold parallel to the deltopectoral groove till the serratus muscle slips appear underneath the pec minor attached to the underlying ribs. Targeting the plane between pec minor and serratus at the level of the third rib, 2 ml of normal saline is injected for confirmation of the needle tip then 20 ml of bupivacaine 0.25%.
This invention relates to the dispensing, creation, and selecting of memory devices that are used with interactive medication containers, dispensers, reminders, or consoles that hold or otherwise organize one or more medication vials or containers. The memory device is attached or adhered to a medication container or vial and has information corresponding to medication and prescription information. The memory device can be prepared when a standard medication label is printed by a pharmacist and can be part of the standard printed label. In other instances the memory device is separate from the medication label. When separate, the memory device has a printed section that identifies the dosing schedule or medication name that corresponds to the reminder schedule the memory device is associated with. The pharmacist or the customer/patient can match the text printed on the memory device with the text of the medical container label to ensure the memory device is only attached to the correct medication container.
Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
The present invention relates to a cough stopping preparation and a preparation method thereof. Chinese ephedra, poppy capsule, liquorice, bitter apricot kernel, etc. are mainly used for preparing oral preparations, such as soft extract, oral liquid, etc. The preparation of the present invention has the efficiency of freeing the lung, clearing heat, stopping cough and relieving asthma, and has obvious effect on treatment of diseases, such as upper respiratory tract infection, tracheitis, pneumonia, cough, etc. In the present invention, a solvent whose pH value is from 2 to 4 is used for extracting the Chinese ephedra and the poppy capsule; meanwhile, the Chinese ephedra and the poppy capsule are soaked for a certain time before being decocted, and then, the dissolution rate of the effective components in the Chinese ephedra and the poppy capsule are effectively improved; the bitter apricot kernel is decocted for 20 to 602 minutes before being decocted, and then, the emulsin is damaged to ensure that the amygdalin is not hydrolyzed; meanwhile, the content of the amygdalin in the preparation is improved, and the functions of the preparation for stopping cough and relieving asthma are enhanced. Conventional cough stopping preparations are prepared into soft extract, oral liquid or syrup to be taken in a drying season to perform the effect of getting twice the result with half the effort; the soft extract, the oral liquid or the syrup is more convenient for children, old people, patients having narrow esophagus and patients having weak gastrointestinal tract functions to take.
INTRODUCTION: Stroke is a potentially debilitating complication of heart valve replacement surgery, with rates ranging from 1 to 10%. Despite advancements in surgical techniques, the incidence of postoperative stroke remains a significant concern, impacting patient outcomes and healthcare resources. This study aims to investigate the incidence, risk factors, and outcomes of in-hospital adverse neurologic events, particularly stroke, following valve replacement. The analysis focuses on identifying patient characteristics and procedural factors associated with increased stroke risk.
METHODS: This retrospective study involves a review of 417 consecutive patients who underwent SVR between January 2004 and December 2022. The study cohort was extracted from a prospectively recorded cardiac intensive care unit database. Preoperative and perioperative data were collected, and subjects with specific exclusion criteria were omitted from the analysis. The analysis includes demographic information, preoperative risk factors, and perioperative variables.
RESULTS: The study identified a 4.3% incidence of postoperative stroke among SVR patients. Risk factors associated with increased stroke susceptibility included prolonged cardiopulmonary bypass time, aortic cross-clamp duration exceeding 90 min, prior stroke history, diabetes mellitus, and mitral valve annulus calcification. Patients undergoing combined procedures, such as aortic valve replacement with mitral valve replacement or coronary artery bypass grafting with AVR and MVR, (OR = 10.74, CI:2.65-43.44, p-value = < 0.001) and (OR = 11.66, CI:1.02-132.70, p-value = 0.048) respectively, exhibited elevated risks. Internal carotid artery stenosis (< 75%) and requiring prolonged inotropic support were also associated with increased stroke risk(OR = 3.04, CI:1.13-8.12, P-value = 0.026). The occurrence of stroke correlated with extended intensive care unit stay (OR = 1.12, CI: 1.04-1.20, P-value = 0.002) and heightened in-hospital mortality.
CONCLUSION: In conclusion, our study identifies key risk factors and underscores the importance of proactive measures to reduce postoperative stroke incidence in surgical valve replacement patients.
Homologous recombination deficiency (HRD) assays are an important element of personalized oncology in ovarian carcinomas, but the optimal tissue requirements for these complex molecular assays remain unclear. As a result, a considerable percentage of assays are not successful, leading to suboptimal diagnoses for these patients. In this study, we have systematically analyzed tumor and tissue parameters for HRD analysis in a large cohort of real-world cancer samples. The aim of this study is to give recommendations for pathologists and gynecologic oncologists for selection of tissue samples to maximize the success rate of HRD analyses. Tumor samples from 2702 patients were sent to the Institute of Pathology of the Philipps-University Marburg between October 2020 and September 2022, of which 2654 were analyzed using the Myriad MyChoice HRD+ CDx assay. A total of 2396 of 2654 samples (90.3%) were successfully tested, of which 984 of 2396 (41.1%) were HRD positive and 1412 (58.9%) were HRD negative. Three hundred sixty-three of 2396 samples (15.2%) were BRCA1/2-mutated; 27 samples had a BRCA1/2 mutation and a genomic instability score (GIS) < 42. Twenty-two samples (0.9%) failed GIS measurement but displayed a BRCA1/2 mutation. BRCA1/2-mutated samples showed significantly (P < .0001) higher GIS values than those with a wild-type BRCA1/2 status. Tumor cell content, tumor area, and histology significantly (P < .0001) affected the probability of successfully analyzing a sample. Based on a systematic analysis of tumor cell content and tumor area, we recommend selecting patient high-grade serous ovarian cancer samples that display a tumor cell content ≥30% and a tumor area ≥0.5 cm2 (based on their hematoxylin and eosin) for HRD testing to allow for optimal chances of a successful analysis and conclusive results. Considering histologic and sample conditions, success rates of up to 98% can be achieved. Our comprehensive evaluation contributes to further standardization of recommendations on HRD testing in ovarian cancer, which will have a large impact on personalized therapeutic strategies in this highly aggressive tumor type.
RATIONALE/OBJECTIVES: Despite plausible pathophysiological mechanisms, research is needed to confirm the relationship between sleep, circadian rhythm and delirium in patients admitted to the intensive care unit (ICU). The objective of this review is to summarise existing studies promoting, in whole or in part, the normalisation of sleep and circadian biology and their impact on the incidence, prevalence, duration and/or severity of delirium in ICU.
METHODS: A sensitive search of electronic databases and conference proceedings was completed in March 2023. Inclusion criteria were English-language studies of any design that evaluated in-ICU non-pharmacological, pharmacological or mixed intervention strategies for promoting sleep or circadian biology and their association with delirium, as assessed at least daily. Data were extracted and independently verified.
RESULTS: Of 7886 citations, we included 50 articles. Commonly evaluated interventions include care bundles (n=20), regulation or administration of light therapy (n=5), eye masks and/or earplugs (n=5), one nursing care-focused intervention and pharmacological intervention (eg, melatonin and ramelteon; n=19). The association between these interventions and incident delirium or severity of delirium was mixed. As multiple interventions were incorporated in included studies of care bundles and given that there was variable reporting of compliance with individual elements, identifying which components might have an impact on delirium is challenging.
CONCLUSIONS: This scoping review summarises the existing literature as it relates to ICU sleep and circadian disruption (SCD) and delirium in ICU. Further studies are needed to better understand the role of ICU SCD promotion interventions in delirium mitigation.
A method may include extracting a plurality of features for each cell depicted in an image. A biomarker identification model may be applied to determine, based on the features associated with each cell, whether the cell is associated with various biomarkers. A set of probabilities for each cell in the population of cells may be determined based on an output of the biomarker identification model. The set of probabilities may include, for each biomarker, a probability of a corresponding cell being associated with the biomarker. One or more subsets of cells, each of which corresponding to a different cellular phenotype, may be identified based on the set of probabilities associated with each cell. A feature set associated with each subset of cells may be identified as being indicative of a probability of a cell being associated with a corresponding phenotype. Related systems and computer program products are also provided.
Products rich in bifidus II factor are produced by subjecting fish intestines, either alone or accompanied by other fish viscera, to autolysis by the action of their own proteolytic enzymes, and then heating the autolysate to deactivate said enzymes.  When the fish intestines make up 5% or less of the total fish viscera, autolysis is carried out in the presence of an added proteolytic enzyme e.g. papain or ficin.  Before autolysis, the total fish viscera may be subjected to a bactericidal treatment by the injection of steam at a temperature of at least 100 DEG C.  The fish viscera may be mixed with animal liver, e.g. ox liver, before autolysis.  After heating, the autolysate is separated and evaporated under reduced pressure to give a mass rich in bifidus II factor.  The bifidus II factor so produced may be mixed with a carrier to form a pharmaceutical composition suitable for oral administration.  The composition may also contain Lactobacillus bifidus and/ or Escherichia coli, and may be in the form of ampoules, capsules or tablets.
PMDS (persistent Müllerian duct syndrome) is a rare disorder of sex development characterised by the presence of Müllerian duct remnants in a phenotypically male individual with a 46XY karyotype. Radiological investigations play a crucial role in diagnosing and characterising this condition. Ultrasound and MRI are the modalities of choice. They help to non-invasively localise the gonads and Müllerian duct derivatives. Broadly, PMDS has two anatomical variants: male type and female type. The case report presented here does not fit into these classically described variants and can be called a variant of the female type. There is a risk of infertility and malignant transformation of undescended testis and Müllerian duct derivatives in cases of PMDS. Hence, management is focused on preventing these risks. Surgical intervention involves orchidopexy, removal of Müllerian duct derivatives and inguinal hernia repair.
Approximately 170 juvenile patients will take part in the study worldwide. All patients will receive 30mg/m2 (milligrams per meter squared, up to 50 mg per dose) of golimumab subcutaneously (injection under the skin) every 4 weeks from Week 0 through Week 12. At Week 16, patients who have shown at least a 30 percent improvement in their signs and symptoms from when they started the study will be randomized to receive either placebo (sham medicine injection) or 30 mg/m2 of golimumab injections every 4 weeks from week 16 through week 48. If a patient gets markedly worse and is receiving placebo injections, they will be restarted on golimumab at the next scheduled visit and will continue on golimumab. Patients can leave the study at any time without question. Between the Week 48 analyses timepoint to Week 144, which is subsequently amended to Week 248, all patients will receive golimumab 30mg/meter squared, unless, by measurements, they have been nearly cured (clinical remission) by being on placebo, whereby they will be discontinued from the study. Patients may have a change in background treatment after Week 48 based on therapeutic effect. Patients will continue active treatment after Week 48 in a long-term extension until Week 144, which is subsequently amended to Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration. Safety will be monitored up to 152 week, which is subsequently amended to 256 weeks including drawing blood and looking at laboratory tests, vital signs (eg, blood pressure), and the frequency and type of adverse events (side effects).
PURPOSE:To obtain a stabilizer of false tooth capable of improving compatibility of false tooth with the gum and stabilizing fitting of base, comprising polyacrylic acid powder and basic compound powder or polyacrylic acid salt powder and organic acid powder and an oil-based ointment base. CONSTITUTION:A pasty stabilizer of false tooth comprising (A) polyacrylic acid powder and basic compound (e.g. CaO or Na2CO3) powder or (B) polyacrylate (e.g. Na salt or ammonium salt) powder and powder of organic acid (e.g. malic acid), phosphoric acid, boric acid or acidic metallic salt thereof and (C) an oil-based ointment base (e.g. vaseline or plastic base). This stabilizer has good flavor and smell, is readily taken out from a container, has excellent feeling in use and can avoid excessive pressure load to local part of gingiva because of somewhat strong ache in hard chewing. The blending ratio of the component A or B and C is preferably (10:90)-(69:31)W/W%.
The present invention discloses an aralkylformylalkyl piperazine derivative and an application thereof as a cranial nerve protectant. The compound aralkylformylalkyl piperazine derivative of the present invention resists ischemic cerebral apoplexy, is especially used as a therapeutical agent for ischemic cerebral infarction in an acute stage and has protective effect on the cranial nerve after ischemic cerebral apoplexy. The present invention can be used for preparing a therapeutical agent for ischemic focal cerebral infarction in the acute stage and a protectant for the cranial nerve after ischemic cerebral apoplexy. The present invention shows preventive and therapeutical effect on animal global cerebral ischemia and focal cerebral ischemia in an animal experiment and has comprehensive effect better than that of the present similar medicine for treating ischemic cerebral infarction in the acute stage and protecting the cranial nerve after cerebral apoplexy. The inventor also discovers that the present invention has lower toxicity and smaller side effect on the central nervous system. The aralkylformylalkyl piperazine derivative is free alkali or salt of the compound having the right upper structure general formula.
During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted in year one. In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children \< 5 years of age presenting to the ED departments.
Scopolamine’s activity is due to the parent drug. The pharmacokinetics of scopolamine delivered via the system are due to the characteristics of both the drug and dosage form. The system is programmed to deliver in-vivo approximately 1.0 mg of scopolamine at an approximately constant rate to the systemic circulation over 3 days. Upon application to the post-auricular skin, an initial priming dose of scopolamine is released from the adhesive layer to saturate skin binding sites. The subsequent delivery of scopolamine to the blood is determined by the rate controlling membrane and is designed to produce stable plasma levels in a therapeutic range. Following removal of the used system, there is some degree of continued systemic absorption of scopolamine bound in the skin layers.

Absorption: Scopolamine is well-absorbed percutaneously. Following application to the skin behind the ear, circulating plasma levels are detected within 4 hours with peak levels being obtained, on average, within 24 hours. The average plasma concentration produced is 87 pg/mL for free scopolamine and 354 pg/mL for total scopolamine (free + conjugates).

Distribution: The distribution of scopolamine is not well characterized. It crosses the placenta and the blood brain barrier and may be reversibly bound to plasma proteins.

Metabolism: Although not well characterized, scopolamine is extensively metabolized and conjugated with less than 5% of the total dose appearing unchanged in the urine.

Elimination: The exact elimination pattern of scopolamine has not been determined. Following patch removal, plasma levels decline in a log linear fashion with an observed half-life of 9.5 hours. Less than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.

Clinical Results: In 195 adult subjects of different racial origins who participated in clinical efficacy studies at sea or in a controlled motion environment, there was a 75% reduction in the incidence of motion-induced nausea and vomiting3.

In two pivotal clinical efficacy studies in 391 adult female patients undergoing cesarean section or gynecological surgery with anesthesia and opiate analgesia, 66% of those treated with Transderm Scōp (compared to only 46% of those receiving placebo) reported no retching/vomiting within the 24-hour period following administration of anesthesia/opiate analgesia. When the need for additional antiemetic medication was assessed during the same period, there was no need for medication in 76% of patients treated with Transderm Scōp as compared to 59% of placebo-treated patients 4, 5.
Xixin-Ganjiang herb pair (XGHP) is a classic combination for warming the lungs to dissolve phlegm and is often used to treat a variety of chronic lung diseases; it can treat the syndrome of cold phlegm obstruction of lungs. First, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to examine the composition of XGHP, and network pharmacology was used to predict its potential core targets and signaling pathways in the current study. Second, a rat model of chronic obstructive pulmonary disease (COPD) was established for assessing the anti-COPD activity of XGHP, and metabolomics was used to explore the biomarkers and metabolic pathways. Finally, the sample was validated using molecular docking and Western blotting. The integration of metabolomics and network pharmacology results identified 11 targets, 3 biomarkers, 3 pathways, and 2 metabolic pathways. Western blotting showed that XGHP effectively regulated the expression of core proteins via multiple signaling pathways (downregulation of toll-like receptor 4 [TLR4] and upregulation of serine/threonine-protein kinase 1 [p-AKT1] and nitric oxide synthase 3 [NOS3]). Molecular docking results showed that the 10 potentially active components of XGHP have good affinity with tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase 9 (MMP-9), TLR4, p-AKT1, and NOS3. Our findings suggest that XGHP may regulate glucolipid metabolism, improve energy supply, and inhibit inflammatory responses (TNF-α, IL-6, and MMP-9) via the PI3K-Akt signaling pathway and HIF-1 signaling pathway in the management of COPD.
The present invention relates to a significant improvement in the preparation of a pharmaceutically purified and proven effective product of powdered bovine tracheal cartilage for the treatment of a number of maladies, including such cancers as disclosed in U.S. Pat. No. 4,822,607 and as a food supplement product. This improvement in the process of preparation is a continuation-in-part of my U.S. patent application Ser. No. 08/302,518 filed Nov. 9, 1994, now U.S. Pat. No. 5,503,990. The present improvement over the above referenced U.S. patent application, which is considerably less expensive, is accomplished by replacing the final cryogenic milling process with a new step including subjecting the processed cartilage to an ACM pulverizer mill, then to a Tenberg B cyclone, while the fine dust is collected by a fine dust bag and the cartilage powder is collected and sent to packaging and/or encapsulation.